Medicare can pay for obesity drugs like Wegovy in certain heart patients
Time:2024-05-22 02:19:06 Source:healthViews(143)
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
You may also like
- Who is Jacob Zuma, the former South African president disqualified from next week's election?
- I put my night sweats down to early menopause
- Could you get your best ever career advice from a ROBOT? The pros and cons of using AI on the job
- TOWIE's Chloe Meadows and Sophie Kasaei put on busty displays in form
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East
- Early man's best friend was the fox as the animal was domesticated by humans, research suggests
- Georgia Steel risks an awkward run
- Giant screen falls on stage during concert by Hong Kong boy band Mirror, two performers injured
- Climber found dead on Denali, North America's tallest peak